



**Outpatient Medical Injectable
Rituximab and Biosimilars
Request Form
Fax to 833-581-1861
(Medical Benefit Only)**

Member Name: _____

Member Date of Birth: _____

Member ID (UMI): _____ Medicare Commercial*

Ordering/Attending Provider Name: _____ NPI: _____

Ordering/Attending Provider Address: _____

Office Contact: _____ Phone #: _____ Fax #: _____

Servicing Facility/Vendor Name: _____ Facility NPI: _____

Servicing Facility/Vendor Address: _____

Requested Start Date of Service: _____ ICD10 Diagnosis Code(s): _____

DRUG INFORMATION (please select one)

<u>PREFERRED PRODUCTS FOR ONCOLOGY INDICATIONS</u>	<u>PREFERRED PRODUCT FOR RHEUMATOID ARTHRITIS</u>	<u>NON-PREFERRED**</u>
<input type="checkbox"/> Ruxience (Q5119) <input type="checkbox"/> Riabni (Q5123) <input type="checkbox"/> Rituxan Hycela* (J9311) *Rituxan Hycela policy requires the member to have received at least one full dose of a rituximab product by intravenous infusion	<input type="checkbox"/> Ruxience (Q5119) <input type="checkbox"/> Riabni (Q5123)	<input type="checkbox"/> Rituxan (J9312) <input type="checkbox"/> Truxima (Q5115) Has the member experienced a documented drug therapy failure or intolerance to the preferred products? Ruxience: <input type="checkbox"/> Yes <input type="checkbox"/> No Riabni: <input type="checkbox"/> Yes <input type="checkbox"/> No **A non-preferred product will be considered when the member has a documented drug therapy failure after an adequate therapeutic trial of BOTH preferred products, or BOTH preferred products have not been tolerated or are contraindicated ** <u>Medicare members</u> currently established on a non-preferred therapy are not required to try a preferred option.

Please verify member's eligibility and benefits through the health plan

**Please answer the following for ONCOLOGY indications:
(for non-oncology indications please proceed to question 6)**

1. What type of cancer does the member have (include histology) and what stage disease?	
2. What is the member's chemotherapy regimen?	
3. What line of therapy is this considered (First, Second, Subsequent)?	
4. What previous therapies has the member received? (Please include if the member progressed or relapsed)	
5. Is the member's disease CD20-positive?	<input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NOT APPLICABLE

**Please answer the following for a NON-ONCOLOGY indication:
(In addition please make sure the accurate icd10 diagnosis code was given above)**

6. What medications (if any) has the member previously used for this condition?	
7. What medications (if any) will the member be using in conjunction for the condition?	
8. What is the dose and frequency of the member's treatment?	Dose: _____ Frequency: _____
<u>For Rheumatoid Arthritis indications ONLY</u>	<input type="checkbox"/> YES <input type="checkbox"/> NO
9. Is the member's RA moderately to severely active?	

<input type="checkbox"/> New Start	<input type="checkbox"/> Continuation of Therapy
	Date of last infusion: _____
	Has the member demonstrated disease stability or a beneficial response to therapy?
	<input type="checkbox"/> YES <input type="checkbox"/> NO

Please attach all pertinent clinical information

Attached: YES NO